Breaking News

  • March 12, 2026

  • Simantini Singh Deo

Commit Biologics Appoints Thomas L. F. Montgomery Andresen, Ph.D., As CEO As Company Prepares To Enter Clinical Development Following €21.5M Seed Backing From Novo Holdings
Breaking News

More News

Clearmind Medicine Begins Enrollment For Third Cohort In FDA-Approved Phase I/IIa Trial Of Non-Hallucinogenic AUD Treatment CMND-100

Clearmind Medicine Begins Enrollment For Third Cohort In FDA-Approved ...

Simantini Singh Deo

Bavarian Nordic A/S Expands Partnership With Serum Institute Of India Pvt. Ltd. Through New Manufacturing Agreement For CHIKV VLP Chikungunya Vaccine

Bavarian Nordic A/S Expands Partnership With Serum Institute Of India ...

Simantini Singh Deo

Quoin Pharmaceuticals Receives FDA Fast Track Designation For QRX003 Lotion To Advance Treatment For Netherton Syndrome

Quoin Pharmaceuticals Receives FDA Fast Track Designation For QRX003 L...

Simantini Singh Deo

Mainz Biomed N.V. Appoints Robert P. Liscouski As Chairman and Announces Name Change To Quantum Cyber With New Nasdaq Ticker Launching March 12, 2026

Mainz Biomed N.V. Appoints Robert P. Liscouski As Chairman and Announc...

Simantini Singh Deo

Ad
Advertisement

Interviews & Opinions

Article

“Be Proactive, Not Reactive” - Dr. ARM Rao’s Leadership Philosophy

In this exclusive leadership conversation, Dr. ARM Rao, President of Aurobindo Pharmaceuticals, shares insights from his 35+ year journey in pharma. F...

FT - Dr. A. R. M. Rao

Read More

Ad
Advertisement
Pharma Now

Weekly Pharma insights directly in your inbox

Get most important news delivered to your email inbox

Pharma Now

Weekly Pharma insights directly in your inbox

Get most important news delivered to your email inbox

Ad
Advertisement